Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

INTRODUCTION Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases. Here we assessed the association between expression of sorafenib targets and biomarkers of taxane sensitivity and response to therapy in pre-treatment tumors from patients enrolled in ECOG 2603, a phase III… CONTINUE READING